Stevanato Group Introduces the New Vertiva® 10mL: Expanding Treatment Options With Innovation
Stevanato Group recently announced the expansion of its Vertiva® platform to include a 10mL option for injectable therapies and highly viscous biological drugs. The innovative Vertiva platform, updated for high volumes.
The Vertiva platform offers a versatile, pre-filled, and pre-loaded on-body solution, tailored for large-volume and highly viscous biological drugs. It supports treatments for conditions including cardiovascular, metabolic disorders, oncology, immunology, and pain management. The Vertiva platform stands out due to its innovative design and patient-friendly features:
- Flexible Dosing Profiles: It can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections.
- Multiple capacities: it can accommodate pre-filled glass cartridges available in formats ranging from 3mL up to 10mL.
- Patient Comfort: A wearability study has shown high patient acceptance, with the system adhering securely to the body while allowing freedom of movement.
- Sustainability: A reusable controller paired with a single-use pod reduces electronic waste, advancing sustainability in drug delivery.
To bring Vertiva 10mL to market, Stevanato is partnering with Thermo Fisher Scientific, leveraging its complementary strengths. Stevanato Group will provide its pre-sterilized EZ-fill® cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will handle fill-and-finish and final assembly. For more information, visit www.stevanatogroup.com.
Total Page Views: 464
